Monitor the ECNP conference (Oct 10-13) for actual data readouts from the GH001-TRD-201 and GH001-BD-202 trials, which could provide material catalysts if efficacy or safety results are disclosed.
Price Chart
Executive Summary
GH Research PLC announced via Form 6-K that it will present data from its GH001-TRD-201 and GH001-BD-202 clinical trials at the ECNP annual meeting in October 2026, along with sponsoring an industry satellite symposium. The filing is a routine event notification with no clinical results or financial data disclosed, making it a low-impact, neutral announcement.
Key Facts
- GH Research will present data from GH001-TRD-201 and GH001-BD-202 trials at the 39th ECNP annual meeting (October 10-13, 2026, Munich).
- Three posters will be presented during Poster Session 2 on October 11, 2026.
- The company is sponsoring an industry satellite symposium on October 10, 2026, titled 'Achieving remission in treatment-resistant depression: current evidence and research on rapid-acting antidepressants.'
- No clinical data, efficacy results, or financial figures are disclosed in this filing.
Financial Impact
No financial impact disclosed; the filing is a routine event announcement.
Risk Factors
- Clinical trial data may not meet expectations, leading to negative stock reaction.
- No financial or operational updates provided in this filing; the event is non-binding.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001140361-26-039191 |
| Document: 0001140361-26-039191-index-headers.html | 0001140361-26-039191 |
| Document: 0001140361-26-039191-index.html | 0001140361-26-039191 |
| Document: 0001140361-26-039191.txt | 0001140361-26-039191 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 17d ago | 6-K | $21.11 $18.15 | ▼ −14.02% | ▼ −12.05% | $19.18 (−9.14%) |
Sep 11, 2026 6w ago | 6-K | $27.20 $28.26 | ▲ +3.90% | ▲ +4.12% | $19.18 (−29.49%) |
Aug 6, 2026 11w ago | 6-K | $30.64 $28.19 | ▼ −8.00% | ▼ −9.21% | $19.18 (−37.40%) |
May 14, 2026 23w ago | 424B5 | $22.21 $21.77 | ▲ +1.98% | ▲ +1.26% | $19.18 (+13.64%) |
May 14, 2026 23w ago | 6-K | $22.21 $21.77 | ▼ −1.98% | ▼ −1.26% | $19.18 (−13.64%) |
May 14, 2026 23w ago | Press Release | $22.21 $21.77 | ▼ −1.98% | ▼ −1.26% | $19.18 (−13.64%) |
May 13, 2026 23w ago | 6-K | $22.21 $21.77 | ▲ +1.98% | ▲ +1.26% | $19.18 (+13.64%) |
Apr 29, 2026 25w ago | 424B5 | $19.16 $21.28 | ▼ −11.06% | ▼ −7.95% | $19.18 (−0.10%) |
Apr 1, 2026 29w ago | 3 | $14.57 $15.72 | ▲ +7.89% | ▲ +4.27% | $19.18 (+31.64%) |
Mar 25, 2026 30w ago | Press Release | $13.65 $14.72 | ▲ +7.84% | ▲ +8.08% | $19.18 (+40.51%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers